ENTRY       D11725                      Drug
NAME        Futibatinib (JAN/USAN/INN);
            Lytgobi (TN)
PRODUCT     LYTGOBI (TAIHO PHARMACEUTICAL)
FORMULA     C22H22N6O3
EXACT_MASS  418.1753
MOL_WEIGHT  418.4485
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03208  FGFR inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01EN04
            Product: D11725<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Cholangiocarcinoma (FGFR2 gene fusion) [DS:H00046]
COMMENT     Treatment of advanced solid tumors
TARGET      FGFR2* (CD332) [HSA_VAR:2263v2] [HSA:2263] [KO:K05093]
  PATHWAY   hsa01521(2263)  EGFR tyrosine kinase inhibitor resistance
            hsa04010(2263)  MAPK signaling pathway
            hsa05200(2263)  Pathways in cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
                 L01EN04 Futibatinib
                  D11725  Futibatinib (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Futibatinib
                D11725  Futibatinib (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11725  Futibatinib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03208  FGFR inhibitor
                 D11725  Futibatinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               FGFR family
                FGFR2* (CD332) [HSA_VAR:2263v2]
                 D11725  Futibatinib (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11725
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11725
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11725
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11725
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11725
DBLINKS     CAS: 1448169-71-8
            PubChem: 405226591
            PDB-CCD: TZ0
ATOM        31
            1   C8y C    37.6672  -21.3804
            2   C8x C    36.4833  -20.7368
            3   C8y C    35.3084  -21.3950
            4   C8x C    35.2549  -22.8133
            5   C8y C    36.3805  -23.4957
            6   C8x C    37.6253  -22.8376
            7   C3b C    34.0742  -20.6542
            8   C3b C    32.9099  -19.9135
            9   C8y C    31.7457  -19.1727
            10  N5x N    31.7992  -17.7543
            11  N4y N    30.4789  -17.2854
            12  C8y C    29.5323  -18.3716
            13  C8y C    30.3655  -19.5002
            14  N5x N    28.1330  -18.5436
            15  C8x C    27.5282  -19.7858
            16  N5x N    28.3613  -20.9145
            17  C8y C    29.7410  -20.8396
            18  N1a N    30.5158  -22.0069
            19  O2a O    36.3699  -24.8944
            20  C1a C    37.5225  -25.5964
            21  O2a O    38.9121  -20.7224
            22  C1a C    40.1346  -21.4244
            23  C1y C    30.0230  -15.9439
            24  C1x C    30.8996  -14.8577
            25  C1x C    30.1248  -13.6902
            26  N1y N    28.7834  -14.0760
            27  C1x C    28.7728  -15.4748
            28  C5a C    27.5411  -13.4712
            29  C2b C    27.5362  -12.0916
            30  O5a O    26.3738  -14.2460
            31  C2a C    26.2240  -11.4867
BOND        34
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     3   7 1
            8     7   8 3
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 1
            13   12  13 1
            14    9  13 1
            15   12  14 2
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   13  17 2
            20   17  18 1
            21    5  19 1
            22   19  20 1
            23    1  21 1
            24   21  22 1
            25   23  11 1 #Down
            26   23  24 1
            27   24  25 1
            28   25  26 1
            29   26  27 1
            30   23  27 1
            31   28  29 1
            32   28  26 1
            33   28  30 2
            34   29  31 2
///
